Global Exosome Diagnostics And Therapeutics Market 2024-2028
The exosome diagnostics and therapeutics market is forecasted to grow by USD 687.63 mn during 2023-2028, accelerating at a CAGR of 23.36% during the forecast period. The report on the exosome diagnostics and therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by raising research on exosome therapeutics, increasing demand for effective drugs for chronic diseases, and growing focus on early detection of cancer.
Technavio's exosome diagnostics and therapeutics market is segmented as below:
By Application
By End-user
- Research and academic institutes
- Pharmaceutical and biotechnology companies
- Commercial
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the advanced technology in exosome collection as one of the prime reasons driving the exosome diagnostics and therapeutics market growth during the next few years. Also, potential of exosomes in personalized medicine and rising focus on regenerative medicine will lead to sizable demand in the market.
The report on the exosome diagnostics and therapeutics market covers the following areas:
- Exosome diagnostics and therapeutics market sizing
- Exosome diagnostics and therapeutics market forecast
- Exosome diagnostics and therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading exosome diagnostics and therapeutics market vendors that include Aethlon Medical Inc., Bio Techne Corp., BioCat GmbH, BioVision Inc., Capricor Therapeutics Inc., Cell Guidance Systems Ltd., Clara Biotech Inc., Evox Therapeutics Ltd., Hologic Inc., JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. and Co. KG, Nanosomix Inc., NX PharmaGen Inc., QIAGEN NV, ReNeuron Group plc, Sarepta Therapeutics Inc, System Biosciences LLC, and Thermo Fisher Scientific Inc.. Also, the exosome diagnostics and therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.